164 studies found for:    "Muscular dystrophy, Duchenne and Becker type"
Show Display Options
Rank Status Study
21 Enrolling by invitation Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Biological: rAAVrh74.MCK.micro-Dystrophin
22 Unknown  Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Biological: human umbilical cord mesenchymal stem cells
23 Unknown  The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
Conditions: Duchenne Muscular Dystrophy;   Cardiomyopathies
Intervention: Drug: Carvedilol
24 Recruiting Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Prednisolone
25 Unknown  Research of Biomarkers in Duchenne Muscular Dystrophy Patients
Condition: Duchenne Muscular Dystrophy (DMD)
Intervention:
26 Unknown  Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)
Condition: Becker Muscular Dystrophy
Intervention: Drug: (-)-epicatechin
27 Withdrawn Test-Retest Reliability of Pulmonary Function Tests in Patients With Duchenne's Muscular Dystrophy
Conditions: Duchenne's Muscular Dystrophy;   Scoliosis
Intervention:
28 Completed Gentamicin Treatment of Muscular Dystrophy
Conditions: Becker Muscular Dystrophy;   Duchenne Muscular Dystrophy
Intervention: Drug: Gentamicin
29 Active, not recruiting Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: PRO045, 0.15 mg/kg/week;   Drug: PRO045, 1.0 mg/kg/week;   Drug: PRO045, 3.0 mg/kg/week;   Drug: PRO045, 6.0 mg/kg/week;   Drug: PRO045, 9.0 mg/kg/week;   Drug: PRO045, selected dose
30 Unknown  Observational Study of Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping
Condition: Duchenne Muscular Dystrophy
Intervention:
31 Active, not recruiting Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Conditions: Becker Muscular Dystrophy;   Sporadic Inclusion Body Myositis
Intervention: Biological: rAAV1.CMV.huFollistatin344
32 Active, not recruiting Efficacy of Stem Cell Therapy in Ambulatory and Non-ambulatory Children With Duchenne Muscular Dystrophy - Phase 1-2
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell
33 Recruiting Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy
Conditions: Muscular Dystrophy;   Duchenne Muscular Dystrophy
Intervention: Other: Intralesional/ Intravenous of Autologous Stem cells.
34 Active, not recruiting A Phase I/II Study of PRO053 in Subjects With Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: Cohort 1;   Drug: Cohort 2;   Drug: 48-week treatment phase
35 Withdrawn A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy (DMD)
Interventions: Drug: Prednisone;   Drug: Placebo
36 Completed
Has Results
DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls
Condition: Duchenne Muscular Dystrophy
Intervention: Other: Testing with EIM
37 Recruiting L-citrulline and Metformin in Duchenne's Muscular Dystrophy
Condition: Duchenne's Muscular Dystrophy (DMD)
Interventions: Drug: 750 mg metformin and 7.5 g L-citrulline daily p.o.;   Drug: Placebo
38 Completed Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Idebenone
39 Completed The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor
Condition: Duchenne Muscular Dystrophy
Intervention:
40 Recruiting A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Biological: PF-06252616;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years